[go: up one dir, main page]

RU2002129298A - APPLICATION OF GALANTAMINE FOR THE TREATMENT OF PSYCHONEUROLOGICAL BEHAVIOR ASSOCIATED WITH ALZHEIMER'S DISEASE - Google Patents

APPLICATION OF GALANTAMINE FOR THE TREATMENT OF PSYCHONEUROLOGICAL BEHAVIOR ASSOCIATED WITH ALZHEIMER'S DISEASE Download PDF

Info

Publication number
RU2002129298A
RU2002129298A RU2002129298/14A RU2002129298A RU2002129298A RU 2002129298 A RU2002129298 A RU 2002129298A RU 2002129298/14 A RU2002129298/14 A RU 2002129298/14A RU 2002129298 A RU2002129298 A RU 2002129298A RU 2002129298 A RU2002129298 A RU 2002129298A
Authority
RU
Russia
Prior art keywords
dose
day
galantamine
administered
use according
Prior art date
Application number
RU2002129298/14A
Other languages
Russian (ru)
Inventor
Вим Луи Жюльен ПАРИС (US)
Вим Луи Жюльен ПАРИС
Майкл ПОНТЕКОРВО (US)
Майкл ПОНТЕКОРВО
Original Assignee
Янссен Фармацевтика Н.В. (Be)
Янссен Фармацевтика Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика Н.В. (Be), Янссен Фармацевтика Н.В. filed Critical Янссен Фармацевтика Н.В. (Be)
Publication of RU2002129298A publication Critical patent/RU2002129298A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)

Claims (11)

1. Применение эффективного количества галантамина или его фармацевтически приемлемой соли для изготовления лекарственного средства для лечения психоневрологического поведения, связанного с болезнью Альцгеймера.1. The use of an effective amount of galantamine or its pharmaceutically acceptable salt for the manufacture of a medicament for the treatment of neuropsychiatric behavior associated with Alzheimer's disease. 2. Применение по п.1, где галантамин вводят в количестве примерно от 1 до примерно 100 мг в день.2. The use according to claim 1, where galantamine is administered in an amount of from about 1 to about 100 mg per day. 3. Применение по п.2, где галантамин вводят в количестве примерно от 5 до примерно 50 мг в день.3. The use according to claim 2, where galantamine is administered in an amount of from about 5 to about 50 mg per day. 4. Применение по п.3, где галантамин вводят в количестве примерно от 16 до примерно 32 мг в день.4. The use according to claim 3, where galantamine is administered in an amount of from about 16 to about 32 mg per day. 5. Применение по п.4, где галантамин вводят в дозе примерно 24 мг/день, причем указанной дозы достигают посредством медленного введения дозы примерно 8 мг/день в течение примерно 1 недели, затем примерно 16 мг/день в течение примерно 1 недели с последующим ежедневным приемом 24 мг/день.5. The use according to claim 4, where galantamine is administered at a dose of about 24 mg / day, and the specified dose is achieved by slowly introducing a dose of about 8 mg / day for about 1 week, then about 16 mg / day for about 1 week subsequent daily intake of 24 mg / day. 6. Применение по п.4, где галантамин вводят в дозе примерно 32 мг/день, причем указанной дозы достигают посредством медленного введения дозы примерно 8 мг/день в течение примерно 1 недели, затем дозы примерно 16 мг/день в течение примерно 1 недели, затем дозы 24 мг/день в течение 1 недели с последующим ежедневным приемом 32 мг/день.6. The use according to claim 4, where galantamine is administered at a dose of about 32 mg / day, and the specified dose is achieved by slowly introducing a dose of about 8 mg / day for about 1 week, then a dose of about 16 mg / day for about 1 week , then a dose of 24 mg / day for 1 week, followed by a daily intake of 32 mg / day. 7. Применение по п.4, где галантамин вводят в дозе примерно от 16 до примерно 24 мг, причем указанной дозы достигают посредством медленного введения в течение периода от примерно 2 до примерно 10 недель при начальной дозе примерно 8 мг, увеличивая дозу до конечного значения дозы примерно 16-24 мг.7. The use according to claim 4, where galantamine is administered in a dose of from about 16 to about 24 mg, and the specified dose is achieved by slow administration for a period of from about 2 to about 10 weeks with an initial dose of about 8 mg, increasing the dose to the final value doses of approximately 16-24 mg. 8. Применение по п.7, где галантамин вводят в дозе около 24 мг/день, причем указанной дозы достигают посредством медленного введения дозы примерно 8 мг/день в течение примерно 2-4 недель, затем дозы примерно 16 мг/день в течение примерно 2-4 недель с последующим ежедневным приемом дозы 24 мг/день.8. The use according to claim 7, where galantamine is administered at a dose of about 24 mg / day, and the specified dose is achieved by slowly introducing a dose of about 8 mg / day for about 2-4 weeks, then a dose of about 16 mg / day for about 2-4 weeks, followed by a daily dose of 24 mg / day. 9. Применение по п.7, где галантамин вводят в дозе около 24 мг/день, причем указанной дозы достигают посредством медленного введения примерно 8 мг/день в течение примерно 4 недель, затем примерно 16 мг/день в течение примерно 4 недель с последующим ежедневным приемом дозы 24 мг/день.9. The use according to claim 7, where galantamine is administered at a dose of about 24 mg / day, and the specified dose is achieved by slow administration of about 8 mg / day for about 4 weeks, then about 16 mg / day for about 4 weeks, followed by daily dose of 24 mg / day. 10. Применение по п.4, где галантамин вводят в дозе примерно 16 мг/день, причем указанной дозы достигают посредством медленного введения дозы примерно 8 мг/день в течение примерно 2-4 недель с последующим ежедневным приемом дозы 16 мг/день.10. The use according to claim 4, where galantamine is administered at a dose of about 16 mg / day, and the specified dose is achieved by slow administration of a dose of about 8 mg / day for about 2-4 weeks, followed by a daily dose of 16 mg / day. 11. Применение по п.9, где галантамин вводят в дозе примерно 16 мг/день, причем указанной дозы достигают посредством медленного введения дозы примерно 8 мг/день в течение примерно 4 недель с последующим ежедневным приемом дозы 16 мг/день.11. The use according to claim 9, where galantamine is administered at a dose of about 16 mg / day, and the specified dose is achieved by slowly administering a dose of about 8 mg / day for about 4 weeks, followed by a daily dose of 16 mg / day.
RU2002129298/14A 2000-04-03 2001-03-28 APPLICATION OF GALANTAMINE FOR THE TREATMENT OF PSYCHONEUROLOGICAL BEHAVIOR ASSOCIATED WITH ALZHEIMER'S DISEASE RU2002129298A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19425900P 2000-04-03 2000-04-03
US60/194,259 2000-04-03

Publications (1)

Publication Number Publication Date
RU2002129298A true RU2002129298A (en) 2004-03-27

Family

ID=22716898

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2002129298/14A RU2002129298A (en) 2000-04-03 2001-03-28 APPLICATION OF GALANTAMINE FOR THE TREATMENT OF PSYCHONEUROLOGICAL BEHAVIOR ASSOCIATED WITH ALZHEIMER'S DISEASE

Country Status (20)

Country Link
EP (1) EP1272192A2 (en)
JP (1) JP2003528913A (en)
KR (1) KR20020086911A (en)
CN (1) CN1430514A (en)
AU (2) AU2001265844B2 (en)
BG (1) BG107093A (en)
BR (1) BR0109770A (en)
CA (1) CA2310926C (en)
CZ (1) CZ20023543A3 (en)
EE (1) EE200200554A (en)
HR (1) HRP20020778A2 (en)
HU (1) HUP0300566A3 (en)
IL (1) IL152061A0 (en)
MX (1) MXPA02009777A (en)
NO (1) NO20024746L (en)
PL (1) PL361272A1 (en)
RU (1) RU2002129298A (en)
SK (1) SK15422002A3 (en)
WO (1) WO2001074339A2 (en)
ZA (1) ZA200207935B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6617361B2 (en) * 1999-11-05 2003-09-09 Be Able, Llc Behavior chemotherapy
PL1651234T3 (en) * 2003-07-25 2008-02-29 Hoffmann La Roche Combination of mglur2 antagonist and ache inhibitor for treatment of acute and/or chronic neurological disorders
DE10338544B4 (en) * 2003-08-19 2017-08-31 Janssen Pharmaceutica N.V. Buccal formulations of galanthamine and their applications
MX347901B (en) 2008-03-27 2017-05-18 Chase Pharmaceuticals Corp Use and composition for treating dementia.
WO2013160728A1 (en) 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Dual targeting compounds for the treatment of alzheimer's disease
BG66818B1 (en) * 2013-03-07 2019-01-31 Berbee Beheer B. V. Composition of hippeastrum papilio extract for the production of medicines and nutritional supplements
WO2016187339A1 (en) * 2015-05-18 2016-11-24 Synaptec Development Llc GALANTAMINE CLEARANCE OF AMYLOIDß
CN117957003A (en) * 2021-09-09 2024-04-30 上海日馨医药科技股份有限公司 Methods of treating neurodegenerative diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
DE19509663A1 (en) * 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Process for the isolation of galanthamine
GB9600080D0 (en) * 1996-01-04 1996-03-06 Chiroscience Ltd Resolution process
EP2311441A1 (en) 1998-11-23 2011-04-20 Bonnie M. Davis Dosage formulations for acetylcholinesterase inhibitors
HRP20010463B1 (en) * 1998-12-24 2011-02-28 Janssen Pharmaceutica N.V. CONTROLLED RELEASE MIXTURES CONTAINING GALANTAMINE
CA2310990A1 (en) * 2000-04-03 2000-10-09 Michael Pontecorvo A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease
CA2310950C (en) * 2000-04-03 2005-11-08 Janssen Pharmaceutica N.V. An efficacious dosage regiment of galantamine that reduces side effects

Also Published As

Publication number Publication date
CZ20023543A3 (en) 2003-03-12
AU6584401A (en) 2001-10-15
IL152061A0 (en) 2003-05-29
WO2001074339A3 (en) 2002-09-12
NO20024746L (en) 2002-11-28
HUP0300566A2 (en) 2003-06-28
BG107093A (en) 2003-06-30
AU2001265844B2 (en) 2005-04-14
CN1430514A (en) 2003-07-16
PL361272A1 (en) 2004-10-04
SK15422002A3 (en) 2003-04-01
CA2310926C (en) 2002-10-15
JP2003528913A (en) 2003-09-30
HRP20020778A2 (en) 2004-04-30
EE200200554A (en) 2004-04-15
BR0109770A (en) 2003-02-04
HUP0300566A3 (en) 2004-10-28
MXPA02009777A (en) 2003-03-27
KR20020086911A (en) 2002-11-20
CA2310926A1 (en) 2000-10-04
ZA200207935B (en) 2004-01-30
NO20024746D0 (en) 2002-10-02
WO2001074339A2 (en) 2001-10-11
EP1272192A2 (en) 2003-01-08

Similar Documents

Publication Publication Date Title
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
ES2089027T3 (en) TRANSMUCOSIC DOSAGE FORM.
RU2008116931A (en) APPLICATION OF N-DESMETHYLCLOSAPINE FOR TREATMENT OF NEUROPSYCHIATRIC DISEASES IN PEOPLE
JP2005515966A5 (en)
MXPA05012810A (en) Memantine oral dosage forms.
JPS59193821A (en) Use of fluoxetin as antianxiety
JP2004537500A5 (en)
MX2024010637A (en) New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases.
EP1372682A4 (en) Catechins for the treatment of fibrillogenesis in alzheimer's disease, parkinson's disease, systemic aa amyloidosis, and other amyloid disorders
RU2002129298A (en) APPLICATION OF GALANTAMINE FOR THE TREATMENT OF PSYCHONEUROLOGICAL BEHAVIOR ASSOCIATED WITH ALZHEIMER'S DISEASE
JP2002544233A5 (en)
JP2003514025A5 (en)
JP2002540148A5 (en)
RU2003127718A (en) APPLICATION OF FLUMAZENIL IN THE PRODUCTION OF A MEDICINE FOR TREATING COCAIN DEPENDENCE
AR023185A1 (en) CANCER TREATMENT IMPROVED WITH TEMOZOLOMIDE
JP2003523385A5 (en)
CA2368352A1 (en) Method for treating neurodegeneration
RU2003100081A (en) METHODS AND COMPOSITIONS IN WHICH SULODEXIDE IS USED FOR THE TREATMENT OF DIABETIC NEPHROPATHY
RU95112520A (en) APPLICATION 4'-IODO-4'-DEOXIDOXORUBICINE FOR THE TREATMENT OF AMYLOIDOSIS, METHOD OF TREATMENT OF AMYLOIDOSIS
RU2006110550A (en) USE OF OXCARBAZEPINE FOR TREATMENT OF DIABETIC NEUROPATHIC PAIN AND FOR IMPROVEMENT OF SLEEP
JPH10175852A5 (en)
EA200300430A1 (en) NEW PHARMACEUTICAL COMPOSITIONS CONTAINING EPINASTINES AND PSEVDOEDFEDRIN
AR020167A1 (en) METHOD FOR PREVENTION OF THE START OF ASTHMA
JPH10175860A5 (en)
RU94023600A (en) METHOD FOR TREATING HEMOCHROMATOSIS

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20060405